Skip to content
Menu

Vanda Pharmaceuticals Settles Patent Infringement Litigation Against MSN Pharmaceuticals With Royalty-Free License For Generic Tasimelteon, Effective From Q1 2040

Benzinga Newsdesk 8 hours ago

News

On November 16, 2026, Vanda Pharmaceuticals Inc. ("Vanda") entered into a Confidential Settlement and License Agreement (the "Settlement Agreement") with MSN Pharmaceuticals Inc. and MSN Laboratories Private Limited (together, "MSN"). The Settlement Agreement settles Vanda’s patent infringement litigation against MSN, Vanda Pharmaceuticals Inc. v. MSN Pharmaceuticals Inc. and MSN Laboratories Private Limited (the "Litigation"), in the U.S. District Court for the District of Delaware (the "Court"). In the Litigation, Vanda alleges that MSN’s Abbreviated New Drug Application ("ANDA") infringes certain U.S. patents owned by Vanda that cover HETLIOZ LQ® (tasimelteon suspension, 4 mg/ml). The ANDA seeks approval to market a generic version of HETLIOZ LQ® in the U.S.

Under the Settlement Agreement, Vanda granted MSN a non-exclusive, royalty-free license to manufacture, import and market MSN’s generic tasimelteon oral suspension in the U.S. on and after the License Effective Date (as defined below). MSN also received limited pre-launch rights to manufacture and import its product (beginning 180 days before the License Effective Date). It may also hold customer discussions and pricing and contracting discussions ahead of launch (beginning 30 days and 14 days before the License Effective Date, respectively).

The "License Effective Date" is in the first quarter of 2040, but MSN may be able to enter the market earlier under certain circumstances. These circumstances include the expiration of the licensed patents, a final court decision that the licensed patents are invalid, unenforceable or not infringed, and the launch of an authorized generic or a licensed generic version of HETLIOZ LQ®. They also include certain unlicensed third-party generic launches that Vanda does not enjoin or otherwise stop within a specified period. MSN may also supply its product before the License Effective Date if the FDA declares a drug shortage after Vanda voluntarily withdraws HETLIOZ LQ® for reasons other than safety or efficacy.

Vanda also agreed that if it later grants any other party certain more favorable terms, including with respect to market-entry timing or pre-launch rights, MSN will receive the benefit of those terms.

Read at benzinga.com